Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine November 2021, 62 (11) 10A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: Johannes Czernin talks with Andrew M. Scott about his role in and perspectives on the extraordinary growth and promise of theranostic applications in nuclear medicine.

Page 1492

Production and supply of α-emitters: Radchenko and colleagues discuss the most promising candidate agents for clinical targeted α-therapy and the current status of global production and supply.

Page 1495

Gut–brain axis imaging in PD: Horsager and colleagues look at the role of radionuclide imaging of the parasympathetic nervous system to investigate autonomic degeneration in patients with Parkinson disease and the potential for exploration of other systemic molecular targets.

Page 1504

Imaging oxidative stress: Greenwood and Witney provide an overview of the latest molecular imaging techniques for elucidating oxidative stress in cancer and highlight the promise for monitoring treatment response and predicting drug resistance.

Page 1506

Parathyroid 18F-fluorocholine PET: Hope and colleagues report on the results of a prospective study designed to determine the correct localization rate of 18F-fluorocholine PET in comparison to 99mTc-sestamibi imaging for detection of parathyroid adenomas.

Page 1511

68Ga-SB3 prostate cancer imaging: Bakker and colleagues investigate the safety and efficacy of PET/CT imaging with this gastrin-releasing peptide-receptor antagonist in therapy-naïve patients before planned prostatectomy.

Page 1517

PET/MRI in pediatric HL: Verhagen and colleagues compare the diagnostic performance of 18F-FDG PET/MRI with a 18F-FDG PET/CT reference standard for staging and response assessment in pediatric and adolescent patients with Hodgkin lymphoma.

Page 1524

Interim PET MTVs in DLBCL: Zwezerijnen and colleagues evaluate semiautomated segmentation methods for delineation of diffuse large B-cell lymphoma lesions and metabolic tumor volumes on interim PET, as well as the effect of lesional SUVmax on this performance.

Page 1531

Antibody-based imaging of nuclear targets: Veal and colleagues describe development of a controlled-expression model of nucleus-localized green fluorescent protein to interrogate the technical limitations of intranuclear SPECT using radioimmunoconjugates.

Page 1537

PSMA and GRPR PET in PCa: Baratto and colleagues compare gastrin-releasing peptide receptor–targeting 68Ga-RM2 PET/MRI with prostate-specific membrane antigen–targeting 68Ga-PSMA11 and 18F-DCFPyL PET/CT in patients with suspected biochemical recurrence of prostate cancer.

Page 1545

Furosemide + PSMA PET in PCa: Uprimny and colleagues assess the impact of forced diuresis with early furosemide injection on 68Ga-PSMA-11 PET/CT detection of local recurrence in prostate cancer and the effects of intravenous furosemide administration on renal tracer washout.

Page 1550

Neoadjuvant PRRT with 177Lu-DOTATATE: Parghane and colleagues report on 177Lu-DOTATATE peptide-receptor radionuclide therapy in the neoadjuvant setting in patients with gastroenteropancreatic neuroendocrine tumors and identify variables associated with primary tumor resectability after PRRT.

Page 1558

64Cu-DOTATATE prognostication algorithm: Carlsen and colleagues hypothesize that in patients with neuroendocrine neoplasms the lesion with the lowest (rather than the highest) 64Cu-DOTATATE uptake on PET/CT is more prognostic and detail a semiautomated method for evaluating this hypothesis.

Page 1564

SSTR antagonist 177Lu-DOTA-LM3 PRRT: Baum and colleagues report on the safety, dosimetry, and efficacy of the somatostatin receptor antagonist 177Lu-DOTA-LM3 in patients with metastatic neuroendocrine neoplasms.

Page 1571

Prognostic use of ventricular morphology: Miller and colleagues assess the independent associations of shape and eccentricity indices from myocardial perfusion SPECT with major adverse cardiovascular events, including analyses of poststress changes in these indices.

Page 1582

Metabolic VT scar assessment: Ghzally and colleagues compare regional 18F-FDG PET tracer uptake with detailed electroanatomic maps in postinfarction patients with ischemic ventricular tachycardia to define the metabolic properties of the tachycardia substrate and successful ablation sites.

Page 1591

Cardiac PET and MBF: Bateman and colleagues from the American Society of Nuclear Cardiology and SNMMI provide a practical guide to interpreting and reporting cardiac PET measurements of myocardial blood flow, to assist physicians in clinical implementation.

Page 1599

Dose–effect in glass 90Y radioembolization: Alsultan and colleagues investigate dose– response and dose–toxicity relationships in patients with colorectal liver metastases treated with glass 90Y-microspheres.

Page 1616

Site-specific 18F-labeled sdAb: Zhou and colleagues evaluate a site-specific strategy for immuno-PET using an 18F residualizing motif and specially engineered anti–epidermal growth factor receptor 2 single-domain antibody fragments.

Page 1624

68Ga peptides for ACE2 detection: Parker and colleagues detail development of angiotensin-converting enzyme 2–specific, peptide-derived 68Ga-labeled radiotracers and investigate their utility in detecting organ-specific suppression of ACE2 in SARS-CoV-2–infected murine models.

Page 1631

LAG-3 imaging and therapy response: Lecocq and colleagues report on a single-domain antibody for nuclear imaging to evaluate whole-body lymphocyte activation gene-3 expression as a next-generation immune checkpoint in various syngeneic mouse cancer models.

Page 1638

Direct AC using DL for SPECT MPI: Yang and colleagues demonstrate a direct attenuation correction technique using deep learning for myocardial perfusion imaging.

Page 1645

PET/CT in hyponatremia: Gans and colleagues present 18F-FDG PET/CT imaging results in the case of a 76-y-old man with hypoosmolar hyponatremia of unknown origin.

Page 1653

  • © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (11)
Journal of Nuclear Medicine
Vol. 62, Issue 11
November 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Nov 2021, 62 (11) 10A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Nov 2021, 62 (11) 10A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • 18F-FDG PET/MRI for Staging and Interim Response Assessment in Pediatric and Adolescent Hodgkin Lymphoma: A Prospective Study with 18F-FDG PET/CT as the Reference Standard
  • PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
  • Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification
  • Practical Guide for Interpreting and Reporting Cardiac PET Measurements of Myocardial Blood Flow: An Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging
  • Direct Attenuation Correction Using Deep Learning for Cardiac SPECT: A Feasibility Study
  • Metabolic Scar Assessment with18F-FDG PET: Correlation to Ischemic Ventricular Tachycardia Substrate and Successful Ablation Sites
  • Cyclic 68Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
  • Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
  • Radionuclide Imaging of the Gut–Brain Axis in Parkinson Disease
  • Dose–Response and Dose–Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer
  • Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study
  • Latest Advances in Imaging Oxidative Stress in Cancer
  • Perspectives on Theranostics and Nuclear Medicine
  • A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes
  • Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy
  • GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients
  • 18F-FDG PET/CT Sheds Light on a Case of Hyponatremia
  • Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma
  • Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
  • Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
  • Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
  • Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
  • First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire